检索结果-南通市图书馆

CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumorassociated macrophage polarization via FBXW7-N0TCHCCL2/ CSF1 axis

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第2期6卷 482-495页

作者： yao-hui huang Kun Cai Peng-Peng Xu Li Wang Chuan-Xin huang Ying Fang Shu Cheng Xiao Jian Sun Feng Liu Jin-Yan huang Meng-Meng Ji Wei-Li Zhao Shanghai Istitute of Hematology State Key Laboratory of Medical GenomicsNational Research Center for Translational Medicine at ShanghaiRulin Hospital Afliated to Shanghai Jiao Tong University School of MedicineShanghaiChina School of Life Sciences and Biotechnology.Shanghai Jiao Tong Universiy ShanghalChina Department of Immunobiology and Microbiology Shanghai Istitute of ImmunologyShanghai Jiao Tong University School of MedicineShanghaiChina Pole de Recherches Sino Francais en Science du Vivant et Genomique Laboratory of Molecular PathologyShanghalChina

Epigenetic alterations play an important role in tumor progression of diffuse large B-cell lymphoma(DL BCL).However,the biological relevance of epigenetic gene mutations on tumor microenvironment remains to be *** core set of genes relating to histone methylation(KMT2D,KMT2C,EZH2),histone acetylation(CREBBP,EP300),DNA methylation(TET2),and chromatin remodeling(ARID1A)were detected in the training cohort of 316 patients by whole-genome/exome sequencing(WGS/WES)and in the validation cohort of 303 patients with newly diagnosed DL BCL by targeted *** correlation with peripheral blood immune cells and clinical outcomes were *** mechanisms on tumor microenvironment were investigated both in vitro and in *** all 619 DLBCL patients,somatic mutations in KMT2D(19.5%)were most frequently observed,followed by mutations in ARID1A(8.7%),CREBBP(8.4%),KMT2C(8.2%),TET2(7.8%),EP300(6.8%),and EZH2(2.9%).Among them,CREBBP/EP300 mutations were signifcantly associated with decreased peripheral blood absolute lymphocyte-to-monocyte ratios,as well as inferior progression-free and overall *** B-lymphoma cells,the mutation or knockdown of CREBBP or EP300 inhibited H3K27 acetylation,downregulated FBXW7 expression,activated the NOTCH pathway,and downstream CCL2/CSF1 expression,resulting in tumor-associated macrophage polarization to M2 phenotype and tumor cell *** B-lymphoma murine models,xenografted tumors bearing CREBBP/EP300 mutation presented lower H3K27 acetylation,higher M2 macrophage recruitment,and more rapid tumor growth than those with CREBBP/EP300 wild-type control via FBXW7-NOTCH-CCL2/CSF1 *** work thus contributed to the understanding of aberrant histone acetylation regulation on tumor microenvironment as an alternative mechanism of tumor progression in DLBCL.

关键词： FBXW7 P300 macrophage

Recent Advances on Ruthenium-based Electrocatalysts for Lithium-oxygen Batteries

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

电化学（中英文） 2024年第8期30卷 1-16页

作者： Yu-Zhe Wang Zhuo-Liang Jiang Bo Wen yao-hui huang Fu-Jun Li Key Laboratory of Advanced Energy Materials Chemistry(Ministry of Education) College of ChemistryNankai UniversityTianjin 300071China Haihe Laboratory of Sustainable Chemical Transformations Tianjin 300192China

Rechargeable lithium-oxygen(Li-O_(2))batteries have attracted wide attention due to their high energy ***,the sluggish cathode kinetics results in high overvoltage and poor cycling ***(Ru)-based electrocatalysts have been demonstrated to be promising cathode catalysts to promote oxygen evolution reaction(OER).It facilitates decomposition of lithium peroxide(Li_(2)O_(2))by adjusting Li_(2)O_(2) morphologies,which is due to the strong interaction between Ru-based catalyst and superoxide anion(O_(2))*** this review,the design strategies of Ru-based electrocatalysts are introduced to enhance their OER catalytic kinetics in Li-O_(2) *** configurations of Ru-based catalysts,including metal particles(Ru metal and alloys),single-atom catalysts,and Ru-loaded compounds with various substrates(carbon materials,metal oxides/sulfides),have been summarized to regulate the electronic structure and the matrix architecture of the Ru-based *** structure-property relationship of Ru-based catalysts is discussed for a better understanding of the Li_(2)O_(2) decomposition mechanism at the cathode ***,the challenges of Ru-based electrocatalysts are proposed for the future development of Li-O_(2) batteries.

关键词： Lithium-oxygen battery Ruthenium-based electrocatalyst Reaction mechanism Reaction kinetics Overvoltage

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

XYZ自动压滤机在铅锌矿废水处理中的应用

过滤与分离 2000年第1期10卷 26-29页

作者：姚辉煌水口山矿务压滤机制造厂湖南常宁421513

介绍了 XYZ自动压滤机及其在铅锌矿废水处理中的应用 ,并给予了一定的分析和肯定。

关键词：自动压滤机脱水速率废水处理铅锌矿

在线全文

学校读者我要写书评

暂无评论

氧化精矿压滤脱水实践

过滤与分离 2000年第2期10卷 41-42页

作者：姚辉煌水口山矿务局压滤机制造厂湖南常宁421513

介绍了一种氧化精矿压滤脱水方法 ,能使氧化精矿压滤脱水水份低 ,产量大 ,效率高。

关键词：氧化精矿双面压滤脱水氧化铝矿压滤脱水

Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2025年第3期31卷 29-41页

作者： Ruo-Yu Guan Jia-Wei Wu Zi-Yun Yuan Zhi-Yuan Liu Zi-Zhu Liu Zhi-Cong Xiao Jing-hui Li Cheng-Zhi huang Jun-Jiang Wang Xue-Qing yao Guangdong Cardiovascular Institute Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesSouthern Medical UniversityGuangzhou 510080Guangdong ProvinceChina Department of Gastrointestinal Surgery Department of General SurgeryGuangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhou 510080Guangdong ProvinceChina Department of General Surgery Guangdong Provincial People’s Hospital Ganzhou Hospital(Ganzhou Municipal Hospital)Ganzhou 341000Jiangxi ProvinceChina Shantou University Medical College Shantou 515041Guangdong ProvinceChina School of Medicine South China University of TechnologyGuangzhou 510006Guangdong ProvinceChina Gannan Medical University Ganzhou 341000Jiangxi ProvinceChina

BACKGROUND Type II diabetes mellitus(T2DM)has been associated with increased risk of colon cancer(CC)and worse prognosis in patients with *** effects of T2DM on postoperative chemoresistance rate(CRR)and long-term disease-free survival(DFS)and overall survival(OS)in patients with stage III CC who receive curative resection remain *** To investigate whether T2DM or glycemic control is associated with worse postoperative survival outcomes in stage III *** This retrospective cohort study included 278 patients aged 40-75 years who underwent surgery for stage III CC from 2018 to *** on preoperative T2DM history,the patients were categorized into non-DM(n=160)and DM groups(n=118).The latter was further divided into well-controlled(n=73)and poorly controlled(n=45)groups depending on the status of glycemic ***,OS,and CRR were compared between the groups and Cox regression analysis was used to identify risk *** Patients in the DM and non-DM groups demonstrated similar DFS,OS,and CRR(DFS:72.03%vs 78.75%,P=0.178;OS:81.36%vs 83.12%,P=0.638;CRR:14.41%vs 7.5%,P=0.063).Poorly controlled DM was associated with a significantly worse prognosis and higher CRR than well-controlled DM(DFS:62.22%vs 78.07%,P=0.021;OS:71.11%vs 87.67%,P=0.011;CRR:24.40%vs 8.22%,P=0.015).High preoperative fasting plasma glucose[DFS:Hazard ratio(HR)=2.684,P<0.001;OS:HR=2.105,P=0.019;CRR:HR=2.214,P=0.005]and glycosylated hemoglobin levels(DFS:HR=2.344,P=0.006;OS:HR=2.119,P=0.021;CRR:HR=2.449,P=0.009)indicated significantly poor prognosis and high CRR,while T2DM history did not(DFS:HR=1.178,P=0.327;OS:HR=0.933,P=0.739;CRR:HR=0.997,P=0.581).CONCLUSION Increased preoperative fasting plasma glucose and glycosylated hemoglobin levels,but not T2DM history,were identified as risk factors associated with poor postoperative outcomes and high CRR in patients with stage III CC.

关键词： Colon cancer Chemoresistance Diabetes mellitus Prognosis Type II diabetes mellitus

Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China:a ***,multicenter,cross-sectional survey

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2017年第8期36卷 352-366页

作者： hui-yao huang Ju-Fang Shi Lan-Wei Guo Ya-Na Bai Xian-Zhen Liao Guo-iangLiu A-Yan Mao Jian-Song Ren Xiao-Jie Sun Xin-Yu Zhu Le Wang Bing-Bing Song Ling-Bin Du Lin Zhu Ji-Yong Gong Qi Zhou Yu-Qin Liu Rong Cao Ling Mai Li Lan Xiao-Hua Sun Ying Ren Jin-Yi Zhou Yuan-Zheng Wang Xiao Qi Pei-An Lou Dian Shi Ni Li Kai Zhang Jie He Min Dai Program Office for Cancer Screening in Urban China National Cancer Center/Cancer HospitalChinese Academy of Medical SciencesPeking Union Medical College17 South Panjiayuan LaneChaoyang DistrictBeijing 100021P.R.China Department of Cancer Epidemiology Henan Cancer HospitalAffiliated Cancer Hospital of Zhengzhou UniversityZhengzhouHenan 450008P.R.China Institute of Epidemiology and Health Statistics Lanzhou UniversityLanzhouGansu 730000P.R.China Hunan Office for Cancer Control and Research Hunan Provincial Cancer HospitalChangshaHunan 410006P.R.China Department of Health Economics School of Health ManagementHarbin Medical UniversityHarbinHeilongjiang 150081P.R.China Public Health Information Research Office Institute of Medical InformationChinese Academy of Medical SciencesBeijing 100020P.R.China Center for Health Management and Policy Key Lab of Health Economics and PolicyShandong UniversityJinanShandong 250012P.R.China Heilongjiang Office for Cancer Control and Research Affiliated Cancer Hospital of Harbin Medical UniversityHarbinHeilongjiang 150081P.R.China Zhejiang Office for Cancer Control and Research Zhejiang Cancer HospitalHangzhouZhejiang 310022P.R.China Teaching and Research Department Affiliated Cancer Hospital of Xinjiang Medical UniversityürümqiXinjiang 830011P.R.China Science and Education Department of Public Health Division Shandong Tumor HospitalJinanShandong 250117P.R.China Chongqing Office for Cancer Control and Research Chongqing Cancer HospitalChongqing 400030P.R.China Cancer Epidemiology Research Center Gansu Provincial Cancer HospitalLanzhouGansu 730050P.R.China Department of Health Policy and Economic Research Guangdong Provincial Institute of Public HealthGuangzhouGuangdong 511430P.R.China Department of Institute of Tumor Research Henan Cancer HospitalAffiliated Cancer Hospital of Zhengzhou UniversityZhengzhouHenan 450008P.R.China Institute of Chronic Disease Prevention and Control Harbin Center for Disease Control and PreventionHarbinHei

Background: The increasing prevalence of colorectal cancer(CRC) in China and the paucity of information about relevant expenditure highlight the necessity of better understanding the financial burden and effect of CRC diagnosis and treatment. We performed a survey to quantify the direct medical and non-medical expenditure as well as the resulting financial burden of CRC patients in ***: We conducted a multicenter, cross-sectional survey in 37 tertiary hospitals in 13 provinces across China between 2012 and 2014. Each enrolled patient was interviewed using a structured questionnaire. All expenditure data were inflated to the 2014 Chinese Yuan(CNY; 1 CNY = 0.163 USD). We quantified the overall expenditure and financial burden and by subgroup(hospital type, age at diagnosis, sex, education, occupation, insurance type, household income, clinical stage, pathologic type, and therapeutic regimen). We then performed generalized linear modeling to determine the factors associated with overall ***: A total of 2356 patients with a mean age of 57.4 years were included, 57.1 % of whom were men; 13.9% of patients had stage I cancer; and the average previous-year household income was 54,525 *** overall average direct expenditure per patient was estimated to be 67,408 CNY, and the expenditures for stage Ⅰ, Ⅱ, Ⅲ, and Ⅳ disease were 56,099 CNY, 59,952 CNY, 67,292 CNY, and 82,729 CNY, respectively. Non-medical expenditure accounted for 8.3%of the overall expenditure. The 1-year out-of-pocket expenditure of a newly diagnosed patient was 32,649 CNY, which accounted for 59.9% of their previous-year household income and caused 75.0% of families to suffer an unmanageable financial burden. Univariate analysis showed that financial burden and overall expenditure differed in almost all subgroups(P < 0.05), except for sex. Multivariate analysis showed that patients who were treated in specialized hospitals and those who were diagnosed with adenocarcinoma or diagno

关键词： Colorectal neoplasms Direct expenditure Financial burden China

在线全文

学校读者我要写书评

暂无评论

消除液压锁液压冲击的探讨

液压与气动 2000年第1期24卷 37-37页

作者：姚辉煌水口山矿务局压滤机制造厂湖南省常宁市松柏镇421513

我厂系生产自动压滤机的专业厂家。液压锁是我厂产品上的常用元件,其中带卸荷阀芯的液压锁应用原理如图1所示。由于进货厂家或者批次不同,液压锁反向开启时,有些有液压冲击现象发生,有些又没有,有些又非常厉害。随着产品销量的不断增长... 详细信息

我厂系生产自动压滤机的专业厂家。液压锁是我厂产品上的常用元件,其中带卸荷阀芯的液压锁应用原理如图1所示。由于进货厂家或者批次不同,液压锁反向开启时,有些有液压冲击现象发生,有些又没有,有些又非常厉害。随着产品销量的不断增长,液压冲击问题尤为突出。为此,曾采取...

关键词：自动压滤机液压锁液压冲击

Medical expenditure for esophageal cancer in China:a 10-year multicenter retrospective survey(2002-2011)

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2017年第11期36卷 548-559页

作者： Lan-Wei Guo hui-yao huang Ju-Fang Shi Li-Hong Lv Ya-Na Bai A-Yan Mao Xian-Zhen Liao Guo-Xiang Liu Jian-Song Ren Xiao-Jie Sun Xin-Yu Zhu Jin-Yi Zhou Ji-Yong Gong Qi Zhou Lin Zhu Yu-Qin Liu Bing-Bing Song Ling-Bin Du Xiao-Jing Xing Pei-An Lou Xiao-Hua Sun Xiao Qi Shou-Ling Wu Rong Cao Li Lan Ying Ren Kai Zhang Jie He Jian.Gong Zhang Min Dai Department of Cancer Epidemiology Henan Office for Cancer Control and Research The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital No. 127 Dongming Road Zhengzhou 450008 Henan P. R China Program Office for Cancer Screening in Urban China Cancer Hospital Chinese Academy of Medical Sciences (CAMS) Peking Union Medical College National Cancer Center of China No. 17 Panjiayuannanli Chaoyang District Beijing 100021 P. R. China Department of Human Resources The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou 450008 Henan P. R. China Institute of Epidemiology and Health Statistics Lanzhou University Lanzhou 730000 Gansu P. R. China Public Health Information Research Office Institute of Medical Information Chinese Academy of Medical Sciences (CAMS) Beijing 100020 P. R. China Hunan Office for Cancer Control and Research Hunan Provincial Cancer Hospital Changsha 410006 Hunan P. R. China Department of Health Economics School of Health Management Harbin Medical University Harbin 150081 Heilongjiang P. R. China Center for Health Management and Policy Key Lab of Health Economics and Policy Shandong University Jinan 250012 Shandong P. R. China Institute of Chronic Non.Communicable Diseases Prevention and Control Jiangsu Provincial Center for Disease Control and Prevention Nanjing 210009 Jiangsu P. R. China Science and Education Department Public Health Division Shandong Tumor Hospital Jinan 250117 Shandong P. R. China Chongqing Office for Cancer Control and Research Chongqing Cancer Hospital Chongqing 400030 P. R. China Teaching and Research Department Affiliated Cancer Hospital of Xinjiang Medical University ürümqi 830011 Xinjiang P. R. China Cancer Epidemiology Research Center Gansu Provincial Cancer Hospital Lanzhou 730050 Gansu P. R. China Heilongjiang Office for Cancer Control and Research Affiliated Cancer Hospital of Harbin Medical University Harbin 150081 Heilongjiang P R. China Zhejiang Office for Cancer

Background: Esophageal cancer is associated with substantial disease burden in China, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnosis and treatment of esophageal cancer in China has not been fully quantified. This study aimed to examine the medical expenditure of Chinese patients with esophageal cancer and the associated ***: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 37 hospitals in 13 provinces/municipalities across China as a part of the Cancer Screening Program of Urban China. For each esophageal cancer patient diagnosed between 2002 and 2011, clinical information and expense data were extracted by using structured questionnaires. All expense data were reported in Chinese Yuan(CNY; 1 CNY = 0.155 USD) based on the2011 value and inflated using the year-specific health care consumer price index for ***: A total of 14,967 esophageal cancer patients were included in the analysis. It was estimated that the overall average expenditure per patient was 38,666 CNY, and an average annual increase of 6.27% was observed from 2002(25,111 CNY) to 2011(46,124 CNY). The average expenditures were 34,460 CNY for stage Ⅰ,39,302 CNY for stage Ⅱ,40,353 CNY for stage Ⅲ, and 37,432 CNY for stage IV diseases(P < 0.01). The expenditure also differed by the therapy type, which was 38,492 CNY for surgery, 27,933 CNY for radiotherapy, and 27,805 CNY for chemotherapy(P < 0.05).Drugs contributed to 45.02% of the overall ***: These conservative estimates suggested that medical expenditures for esophageal cancer in China substantially increased in the last 10 years, treatment for early-stage esophageal cancer costs less than that for advanced cases, and spending on drugs continued to account for a considerable proportion of the overall expenditure.

关键词： Esophageal neoplasms Medical expenditure Diagnosis and treatment China

Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus:A case report

在线全文

学校读者我要写书评

暂无评论

World Journal of Diabetes 2025年第1期16卷 204-210页

作者： Fang Chen Bo An Wen-Cheng An Gang Fu Wei huang hui-Xian Yan Department of Endocrinology Beijing Haidian HospitalBeijing 100080China Department of Nephrology Beijing Haidian HospitalBeijing Haidian Section of Peking University Third HospitalBeijing 100080China

BACKGROUND Treating diabetes in dialysis patients remains a challenge,with many hypoglycemic drugs requiring dose adjustments or avoidance in these *** SUMMARY This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes(T2DM)who had struggled to control her blood sugar for more than a *** had a history of high blood pressure for 30 years,had undergone continuous ambulatory peritoneal dialysis for more than two years,was 163 cm tall,weighed 77 kg,and had a body mass index of 28.98 kg/*** intensive insulin therapy at a daily dose of 150 units,adding Dorzagliatin at a dosage of 75 mg orally twice daily led to immediate blood sugar improvement and a gradual reduction in insulin *** one month of follow-up,the fasting plasma glucose was 6-8 mmol/L,and the 2-hour postprandial glucose was 8-12 mmol/*** To our knowledge,this report is the first to use Dorzagliatin to treat type 2 diabetes peritoneal dialysis patients with challenging glucose ***,a novel glucokinase activator primarily metabolized by the liver,exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney *** has a high plasma protein binding rate and may not be cleared by peritoneal dialysis,potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis.

关键词： Dorzagliatin Type 2 diabetes mellitus Peritoneal dialysis Glucokinase activator Glucose control Case report